乳腺癌外泌体及相关miRNA的研究进展

doi:10.16139/j.1007-9610.2018.06.021

摘要/Abstract

中图分类号:

R737.9

李小燕, 贺靖, 邹强. 乳腺癌外泌体及相关miRNA的研究进展[J]. 外科理论与实践, 2018, 23(06): 564-568.

[1] Li T, Mello-Thoms C, Brennan PC.Descriptive epidemio-logy of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat,2016,159(3):395-406.
[2] Pan BT, Johnstone RM.Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor[J]. Cell,1983,33(3):967-978.
[3] Davis JQ, Dansereau D, Johnstone RM, et al.Selective externalization of an ATP-binding protein structurally related to the clathrin-uncoating ATPase/heat shock protein in vesicles containing terminal transferrin receptors du-ring reticulocyte maturation[J]. J Biol Chem,1986,261(33):15368-15371.
[4] Johnstone RM, Adam M, Hammond JR, et al.Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)[J]. J Biol Chem,1987,262(19):9412-9420.
[5] Valadi H, Ekstrom K, Bossios A, et al.Exosome-media-ted transfer of mRNAs and microRNAs is a novel mecha-nism of genetic exchange between cells[J]. Nat Cell Biol,2007,9(6):654-659.
[6] Iero M, Valenti R, Huber V, et al.Tumour-released exosomes and their implications in cancer immunity[J]. Cell Death Differ,2008,15(1):80-88.
[7] Yu S, Cao H, Shen B, et al.Tumor-derived exosomes in cancer progression and treatment failure[J]. Oncotarget,2015,6(35):37151-37168.
[8] Thery C, Ostrowski M, Segura E.Membrane vesicles as conveyors of immune responses[J]. Nat Rev Immunol,2009,9(8):581-593.
[9] Zhang HG, Grizzle WE.Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions[J]. Am J Pathol,2014,184(1):28-41.
[10] Vader P, Breakefield XO, Wood MJ.Extracellular vesicles: emerging targets for cancer therapy[J]. Trends Mol Med,2014,20(7):385-393.
[11] Kooijmans SA, Vader P, van Dommelen SM, et al. Exosome mimetics: a novel class of drug delivery systems[J]. Int J Nanomedicine,2012,7:1525-1541.
[12] van Niel G, Porto-Carreiro I, Simoes S, et al. Exosomes: A common pathway for a specialized function[J]. J Biochem,2006,140(1):13-21.
[13] Cocucci E, Meldolesi J.Ectosomes and exosomes: shedding the confusion between extracellular vesicles[J]. Trends Cell Biol,2015,25(6):364-372.
[14] Antonyak MA, Li B, Boroughs LK, et al.Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells[J]. Proc Natl Acad Sci U S A,2011,108(12):4852-4857.
[15] Singh R, Pochampally R, Watabe K, et al.Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer[J]. Mol Cancer,2014,13:256.
[16] Gernapudi R, Yao Y, Zhang Y, et al.Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer[J]. Breast Cancer Res Treat,2015,150(3):685-695.
[17] Camacho L, Guerrero P, Marchetti D.MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes[J]. PLoS One,2013,8(9):e73790.
[18] Gwak JM, Kim HJ, Kim EJ, et al.MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer[J]. Breast Cancer Res Treat,2014,147(1):39-49.
[19] Baroni S, Romero-Cordoba S, Plantamura I, et al.Exosome-mediated delivery of miR-9 induces cancer-associa-ted fibroblast-like properties in human breast fibroblasts[J]. Cell Death Dis,2016,7(7):e2312.
[20] Tkach M, Thery C.Communication by extracellular vesicles: where we are and where we need to go[J]. Cell,2016,164(6):1226-1232.
[21] Ma L, Young J, Prabhala H, et al.miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis[J]. Nat Cell Biol,2010,12(3):247-256.
[22] O'Brien K, Rani S, Corcoran C, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells[J]. Eur J Cancer,2013,49(8):1845-1859.
[23] Luga V, Zhang L, Viloria-Petit AM, et al.Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration[J]. Cell,2012,151(7):1542-1556.
[24] Nabet BY, Qiu Y, Shabason JE, et al.Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer[J]. Cell,2017,170(2):352-366.
[25] Wen SW, Sceneay J, Lima LG, et al.The biodistribution and immune suppressive effects of breast cancer-derived exosomes[J]. Cancer Res,2016,76(23):6816-6827.
[26] Munich S, Sobo-Vujanovic A, Buchser WJ, et al.Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands[J]. Oncoimmunology,2012,1(7):1074-1083.
[27] Rong L, Li R, Li S, et al.Immunosuppression of breast cancer cells mediated by transforming growth factor-beta in exosomes from cancer cells[J]. Oncol Lett,2016,11(1):500-504.
[28] Hong EH, Chang SY, Lee BR, et al.Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells[J]. Int J Cancer,2013,132(12):2839-2848.
[29] Liu C, Yu S, Zinn K, et al.Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function[J]. J Immunol,2006,176(3):1375-1385.
[30] Clayton A, Tabi Z.Exosomes and the MICA-NKG2D system in cancer[J]. Blood Cells Mol Dis,2005,34(3):206-213.
[31] Clayton A, Mitchell JP, Court J, et al.Human tumor-derived exosomes down-modulate NKG2D expression[J]. J Immunol,2008,180(11):7249-7258.
[32] Gobbo J, Marcion G, Cordonnier M, et al.Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer[J]. J Natl Cancer Inst,2016,108(3).doi:10.1093
[33] Shedden K, Xie XT, Chandaroy P, et al.Expulsion of small molecules in vesicles shed by cancer cells: associa-tion with gene expression and chemosensitivity profiles[J]. Cancer Res,2003,63(15):4331-4337.
[34] Safaei R, Larson BJ, Cheng TC, et al.Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells[J]. Mol Cancer Ther,2005,4(10):1595-1604.
[35] Ciravolo V, Huber V, Ghedini GC, et al.Potential role of HER2-overexpressing exosomes in countering trastuzu-mab-based therapy[J]. J Cell Physiol,2012,227(2):658-667.
[36] Lv MM, Zhu XY, Chen WX, et al.Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein[J]. Tumour Biol,2014,35(11):10773-10779.
[37] Mao L, Li J, Chen WX, et al.Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs[J]. Tumour Biol,2016,37(4):5247-5256.
[38] Wei Y, Lai X, Yu S, et al.Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells[J]. Breast Cancer Res Treat,2014, 147(2):423-431.
[39] Boelens MC, Wu TJ, Nabet BY, et al.Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways[J]. Cell,2014,159(3):499-513.
[40] Pigati L, Yaddanapudi SC, Iyengar R, et al.Selective release of microRNA species from normal and malignant mammary epithelial cells[J]. PLoS One,2010,5(10): e13515.
[41] Eichelser C, Stuckrath I, Muller V, et al.Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients[J]. Oncotarget,2014,5(20):9650-9663.
[42] Hannafon BN, Trigoso YD, Calloway CL, et al.Plasma exosome microRNAs are indicative of breast cancer[J]. Breast Cancer Res,2016,18(1):90.
[43] Fang S, Tian H, Li X, et al.Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification[J]. PLoS One,2017,12(4):e175050.
[44] Kibria G, Ramos EK, Lee KE, et al.A rapid, automated surface protein profiling of single circulating exosomes in human blood[J]. Sci Rep,2016,6:36502.
[45] Lee SJ, Lee J, Kim WW, et al.Del-1 expression as a potential biomarker in triple-negative early breast cancer[J]. Oncology,2018,94(4):243-256.
[46] Joyce DP, Kerin MJ, Dwyer RM.Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer[J]. Int J Cancer,2016,139(7):1443-1448.
[47] Kim MS, Haney MJ, Zhao Y, et al.Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells[J]. Nanomedicine,2016,12(3):655-664.
[48] Pi F, Binzel DW, Lee TJ, et al.Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression[J]. Nature Nanotechnol,2018,13(1):82-89.

乳腺癌外泌体及相关miRNA的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张小丽　李赞　宋达疆　王业成　海涛. 带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-.
[2]	宋达疆　李赞　章一新. 带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[3]	纪鸥洋　方均燕　宋阿会　佟琰　魏珊　陈志豪　刘英莉. 间充质干细胞外泌体对腹膜间皮细胞高糖损伤的作用研究[J]. 组织工程与重建外科杂志, 2022, 18(4): 294-.
[4]	陈辉　侯爱华　王培培　梅晓峰. 增强型绿色荧光蛋白标记膀胱癌外泌体的构建及其体外示踪作用[J]. 组织工程与重建外科杂志, 2022, 18(4): 300-.
[5]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲. 硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[6]	廖晓明　蒋奕　唐玮　杨华伟　姬逸男　韦莉颖. 薄层血管化腹股沟淋巴结皮瓣移植联合反向淋巴显影在继发性上肢淋巴水肿手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(1): 8-.
[7]	宋景涌汤鹏钟晓捷刘侠孙洋亢玉王遥佳陈安玥陈怡安吉训通周艳虹蒋曼妃修骋穆籣. 吻合口通畅性量化分析应用于乳腺癌腋窝淋巴结清扫术同期预防性淋巴管静脉吻合1例[J]. 组织工程与重建外科杂志, 2022, 18(1): 34-.
[8]	陈小松, 沈坤炜, 李宏为. 早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386.
[9]	吴佳毅, 陆裕杰, 何金光, 沈坤炜, 徐华. 乳腺癌术后植入物乳房重建技术[J]. 外科理论与实践, 2022, 27(05): 387-391.
[10]	陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.
[11]	谢妍妍, 吕青, 杜正贵. 乳腺腔镜和机器人手术的现状及未来之路——华西医院经验分享[J]. 外科理论与实践, 2022, 27(05): 396-402.
[12]	周文斌, 唐新宇, 王水. 局部微波消融技术在乳腺癌治疗中的应用[J]. 外科理论与实践, 2022, 27(05): 403-405.
[13]	曹璐, 郑思悦, 陈佳艺. 早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.
[14]	黄蔚, 李恒宇, 丁晓毅. 晚期乳腺癌介入诊疗的价值及应用[J]. 外科理论与实践, 2022, 27(05): 411-415.
[15]	舒兰, 陈小松. ER⁺/HER2^-乳腺癌多基因阵列检测应用：ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022, 27(05): 416-420.